Keywords:
Neoplasia, Metabolic disorders, Education, Diagnostic procedure, PET-CT, Nuclear medicine conventional, MR, Musculoskeletal soft tissue, Musculoskeletal bone, Bones
Authors:
B. D. Nguyen, C. Adler; Scottsdale, AZ/US
DOI:
10.1594/essr2018/P-0054
Conclusion
The viewers will be familiar with phosphaturic mesenchymal tumors with the following take-home points:
1. OO,
an uncommon paraneoplastic disorder,
is related to phosphaturic lesions mostly composed of hemangiopericytomas and mesenchymal tumors.
2. Its pathophysiology rests on tumor-released phosphaturic phosphatonins such as FGF-23,
which is a useful tumor maker for OO diagnosis and posttherapeutic surveillance.
3. Hypophosphatemic disorders XLH and ADHR share intricate FGF-23,
PHEX and MEPE pathways of phosphate wasting disorder and represent potential differential diagnosis of OO in young patients.
4. Even with an established diagnosis of OO,
the search for incriminating tumor remains frustratingly time-consuming and frequently unsuccessful.
5. Combined anatomic (CT,
MR) and functional imaging ( Tc-99 m sestamibi,
In-111 octreotide,
F-18 FDG PET/CT and presently Ga-68 DOTATATE PET/CT) may help the timely detection and localization of causative phosphaturic tumors.